Unexpected reduction of skin tumorigenesis on expression of cyclin-dependent kinase 6 in mouse epidermis

American Journal of Pathology

Volumn 178, Issue 1, 2011, Pages 345-354

  Wang, Xian ^a   Sistrunk, Christopher ^a   Rodriguez Puebla, Marcelo L ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D3; CYCLIN DEPENDENT KINASE 6; CYTOKERATIN 5; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CHEMICAL ANALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; EPIDERMIS; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN TUMOR;

EID: 79251475581     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.11.032     Document Type: Article

References (66)

1. Sherr CJ: D-type cyclins. Trends Biochem Sci 1995, 20:187-190
2. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330
3. Blain SW, Montalvo E, Massague J: Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. J Biol Chem 1997, 272:25863-25872 (Pubitemid 27438911)
4. Sherr CJ, McCormick F: The RB and p53 pathways in cancer. Cancer Cell 2002, 2:103-112
5. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 10:1491-1502
6. Meyerson M, Harlow E: Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 1994, 14:2077-2086
7. Lucas JJ, Szepesi A, Modiano JF, Domenico J, Gelfand EW: Regulation of synthesis and activity of the PLSTIRE protein (cyclin-dependent kinase 6 (cdk6)), a major cyclin D-associated cdk4 homologue in normal human T lymphocytes. J Immunol 1995, 154:6275-6284
8. Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, Ortega S, Dubus P, Barbacid M: Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004, 118:493-504
9. Hu MG, Deshpande A, Enos M, Mao D, Hinds EA, Hu GF, Chang R, Guo Z, Dose M, Mao C, Tsichlis PN, Gounari F, Hinds PW: A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res 2009, 69:810-818
10. Bockstaele L, Bisteau X, Paternot S, Roger PP: Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation. Mol Cell Biol 2009, 29:4188-4200
11. Takaki T, Fukasawa K, Suzuki-Takahashi I, Semba K, Kitagawa M, Taya Y, Hirai H: Preferences for phosphorylation sites in the retinoblastoma protein of D-type cyclin-dependent kinases. Cdk4 and Cdk6, in vitro. J Biochem 2005, 137:381-386
12. Grossel MJ, Baker GL, Hinds PW: cdk6 can shorten G(1) phase dependent upon the N-terminal INK4 interaction domain. J Biol Chem 1999, 274:29960-29967
13. Ericson KK, Krull D, Slomiany P, Grossel MJ: Expression of cyclin-dependent kinase 6, but not cyclin-dependent kinase 4, alters morphology of cultured mouse astrocytes. Mol Cancer Res 2003, 1:654-664 (Pubitemid 36870518)
14. Matushansky I, Radparvar F, Skoultchi AI: CDK6 blocks differentiation: coupling cell proliferation to the block to differentiation in leukemic cells. Oncogene 2003, 22:4143-4149
15. Ogasawara T, Kawaguchi H, Jinno S, Hoshi K, Itaka K, Takato T, Nakamura K, Okayama H: Bone morphogenetic protein 2-induced osteoblast differentiation requires Smad-mediated down-regulation of Cdk6. Mol Cell Biol 2004, 24:6560-6568
16. Ogasawara T, Katagiri M, Yamamoto A, Hoshi K, Takato T, Nakamura K, Tanaka S, Okayama H, Kawaguchi H: Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6). J Bone Miner Res 2004, 19:1128-1136
17. Nagasawa M, Gelfand EW, Lucas JJ: Accumulation of high levels of the p53 and p130 growth-suppressing proteins in cell lines stably over-expressing cyclin-dependent kinase 6 (cdk6). Oncogene 2001, 20:2889-2899 (Pubitemid 33027756)
18. Lucas JJ, Terada N, Szepesi A, Gelfand EW: Regulation of synthesis of p34cdc2 and its homologues and their relationship to p110Rb phosphorylation during cell cycle progression of normal human T cells. J Immunol 1992, 148:1804-1811
19. Lucas JJ, Szepesi A, Domenico J, Tordai A, Terada N, Gelfand EW: Differential regulation of the synthesis and activity of the major cyclin-dependent kinases, p34cdc2, p33cdk2, and p34cdk4, during cell cycle entry and progression in normal human T lymphocytes. J Cell Physiol 1995, 165:406-416
20. Costello JF, Plass C, Arap W, Chapman VM, Held WA, Berger MS, Su Huang HJ, Cavenee WK: Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 1997, 57:1250-1254
21. Ichimura K, Schmidt EE, Goike HM, Collins VP: Human glioblastomas with no alterations of the CDKN2A (p16INK4A. MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996, 13:1065-1072
22. Lam PY, Di Tomaso E, Ng HK, Pang JC, Roussel MF, Hjelm NM: Expression of p19INK4d. CDK4, CDK6 in glioblastoma multiforme. Br J Neurosurg 2000, 14:28-32
23. Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/ MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994, 54:6321-6324
24. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996, 12:97-99
25. Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde KH, Beach D: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269:1281-1284
26. Timmermann S, Hinds PW, Munger K: Elevated activity of cyclin-dependent kinase 6 in human squamous cell carcinoma lines. Cell Growth Differ 1997, 8:361-370
27. Piboonniyom SO, Timmermann S, Hinds P, Munger K: Aberrations in the MTS1 tumor suppressor locus in oral squamous cell carcinoma lines preferentially affect the INK4A gene and result in increased cdk6 activity. Oral Oncol 2002, 38:179-186
28. Easton J, Wei T, Lahti JM, Kidd VJ: Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma. Cancer Res 1998, 58:2624-2632
29. Zhang S-Y, Liu S-C, Goodrow T, Morris R, Klein-Szanto AJP: Increased expression of G1 cyclins and cyclin-dependent kinases during tumor progression of chemically induced mouse skin neoplasms. Mol Carcinog 1997, 18:142-152
30. Rodriguez-Puebla ML, LaCava M, Gimenez-Conti IB, Johnson DG, Conti CJ: Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin. Oncogene 1998, 17:2251-2258 (Pubitemid 28515377)
31. Rodriguez-Puebla ML, LaCava M, Conti CJ: Cyclin D1 overexpression in mouse epidermis increases cyclin-dependent kinase activity and cell proliferation in vivo but does not affect skin tumor development. Cell Growth Differ 1999, 10:467-472
32. Rodriguez-Puebla ML, Miliani de Marval PL, LaCava M, Moons DS, Kiyokawa H, Conti CJ: Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. Am J Pathol 2002, 161:405-411
33. Miliani de Marval PL, Macias E, Conti CJ, Rodriguez-Puebla MLR: Enhanced malignant tumorigenesis in Cdk4 transgenic miceR. Oncogene 2004, 23R: 1863-1873 (Pubitemid 38445412)
34. Rojas P, Benavides F, Blando J, Perez C, Cardenas K, Richie E, Knudsen ES, Johnson DG, Senderowicz AM, Rodriguez-Puebla ML, Conti CJ: Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b). Mol Carcinog 2009, 48:508-516
35. Macias E, Kim Y, Miliani de Marval PL, Klein-Szanto A, Rodriguez- Puebla ML: Cdk2 deficiency decreases ras/CDK4-dependent malignant progression, but not myc-induced tumorigenesis. Cancer Res 2007, 67:9713-9720
36. Macias E, Miliani de Marval PL, De Siervi A, Conti CJ, Senderowicz AM, Rodriguez-Puebla ML: CDK2 activation in mouse epidermis induces keratinocyte proliferation but does not affect skin tumor development. Am J Pathol 2008, 173:526-535
37. Miliani de Marval PL, Gimenez-Conti IB, LaCava M, Martinez LA, Conti CJ, Rodriguez-Puebla ML: Transgenic expression of cyclin-dependent kinase 4 results in epidermal hyperplasia, hypertrophy, and severe dermal fibrosis. Am J Pathol 2001, 159:369-379
38. Miliani de Marval PL, Macias E, Rounbehler R, Sicinski P, Kiyokawa H, Johnson DG, Conti CJ, Rodriguez-Puebla ML:Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol Cell Biol 2004, 24:7538-7547
39. Rodriguez-Puebla ML, LaCava M, Miliani De Marval PL, Jorcano JL, Richie ER, Conti CJ: Cyclin D2 overexpression in transgenic mice induces thymic and epidermal hyperplasia whereas cyclin D3 expression results only in epidermal hyperplasia. Am J Pathol 2000, 157:1039-1050
40. Rojas P, Cadenas MB, Lin PC, Benavides F, Conti CJ, Rodriguez- Puebla ML: Cyclin D2 and cyclin D3 play opposite roles in mouse skin carcinogenesis. Oncogene 2007, 26:1723-1730
41. Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y, Gardner H, Kiyokawa H, Harris LN, Stal O, Sicinski P: Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006, 9:23-32
42. Zou X, Ray D, Aziyu A, Christov K, Boiko AD, Gudkov AV, Kiyokawa H: Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev 2002, 16:2923-2934
43. Ramirez A, Bravo A, Jorcano J, Vidal M: Sequences 5′ of the bovine keratin 5 gene direct tissue- and cell-type-specific expression of a lacZ gene in the adult and during development. Differentiation 1994, 58:53-64 (Pubitemid 24361127)
44. Rodriguez-Puebla ML, Robles AI, Johnson DG, LaCava M, Conti CJ: Synchronized proliferation induced by 12-O-tetradecanoylphorbol- 13-acetate treatment of mouse skin: an in vivo model for cell cycle regulation. Cell Growth Differ 1998, 9:31-39
45. Ito M, Liu Y, Yang Z, Nguyen J, Liang F, Morris RJ, Cotsarelis G: Stem cells in the hair follicle bulge contribute to wound repair but not to homeostasis of the epidermis. Nat Med 2005, 11:1351-1354
46. Woodcock-Mitchell J, Eichner R, Nelson WG, Sun T: Immunolocalization of keratin polypeptides in human epidermis using monoclonal antibodies. J Cell Biol 1982, 95:580-588
47. Roop D, Hawley-Nelson P, Cheng CK, Yuspa SH: Keratin gene expression in mouse epidermis and cultured epidermal cells. Proc Natl Acad Sci U S A 1983, 80:716-720
48. Ruggeri B, Caamano J, Goodrow T, DiRado M, Bianchi A, Trono D, Conti CJ, Klein-Szanto AJ: Alterations of the p53 tumor suppressor gene during mouse skin tumor progression. Cancer Res 1991, 51:6615-6621
49. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, Barbacid M: Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 1999, 22:44-52
50. Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, Kiyokawa H: Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol 1999, 19:7011-7019
51. Hakem A, Sasaki T, Kozieradzki I, Penninger JM: The cyclin-dependent kinase Cdk2 regulates thymocyte apoptosis. J Exp Med 1999, 189:957-968
52. Choi KS, Eom YW, Kang Y, Ha MJ, Rhee H, Yoon JW, Kim SJ: Cdc2 and Cdk2 kinase activated by transforming growth factor-beta1 trigger apoptosis through the phosphorylation of retinoblastoma protein in FaO hepatoma cells. J Biol Chem 1999, 274:31775-31783 (Pubitemid 129503760)
53. Maddika S, Ande SR, Wiechec E, Hansen LL, Wesselborg S, Los M: Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J Cell Sci 2008, 121:979-988
54. Gil-Gomez G, Berns A, Brady HJ: A link between cell cycle and cell death: bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis. EMBO J 1998, 17:7209-7218
55. Ruiz S, Santos M, Lara MF, Segrelles C, Ballestin C, Paramio JM: Unexpected roles for pRb in mouse skin carcinogenesis. Cancer Res 2005, 65:9678-9686
56. Ruiz S, Santos M, Paramio JM: Is the loss of pRb essential for the mouse skin carcinogenesis? Cell Cycle 2006, 5:625-629
57. Nerlov C: The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol 2007, 17:318-324
58. Grossel MJ, Hinds PW: From cell cycle to differentiation: an expanding role for cdk6. Cell Cycle 2006, 5:266-270 (Pubitemid 43213495)
59. Grossel MJ, Hinds PW: Beyond the cell cycle: a new role for Cdk6 in differentiation. J Cell Biochem 2006, 97:485-493
60. Fujimoto T, Anderson K, Jacobsen SE, Nishikawa SI, Nerlov C: Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPalpha interaction. EMBO J 2007, 26:2361-2370
61. Hoi CS, Lee SE, Lu SY, McDermitt DJ, Osorio KM, Piskun CM, Peters RM, Paus R, Tumbar T: Runx1 directly promotes proliferation of hair follicle stem cells and epithelial tumor formation in mouse skin. Mol Cell Biol 2010, 30:2518-2536
62. Santos M, Ruiz S, Lara MF, Segrelles C, Moral M, Martinez-Cruz AB, Ballestin C, Lorz C, Garcia-Escudero R, Paramio JM: Susceptibility of pRb-deficient epidermis to chemical skin carcinogenesis is dependent on the p107 allele dosage. Mol Carcinog 2008, 47:815-821
63. Blow JJ, Hodgson B: Replication licensing- defining the proliferative state? Trends Cell Biol 2002, 12:72-78
64. Porter AC: Preventing DNA over-replication: a Cdk perspective. Cell Div 2008, 3:3
65. Braden WA, McClendon AK, Knudsen ES: Cyclin-dependent kinase 4/6 activity is a critical determinant of pre-replication complex assembly. Oncogene 2008, 27:7083-7093
66. Wang GL, Shi X, Salisbury E, Sun Y, Albrecht JH, Smith RG, Timchenko NA: Cyclin D3 maintains growth-inhibitory activity of C/ EBPalpha by stabilizing C/EBPalpha-cdk2 and C/EBPalpha-Brm complexes. Mol Cell Biol 2006, 26:2570-2582